Most cases of typhoid or enteric fever are caused by Salmonella enterica subsp. enterica serovar Typhi (S. Typhi), although S. Paratyphi A and B and occasionally other serotypes such as S. Virchov, S. Dublin and S. Newport are implicated. S. Typhi is solely a human pathogen and there is no animal reservoir. Although typhoid is a rare imported infection in developed countries [ 1,2], in developing countries where safe water supply, environmental sanitation and food hygiene are not optimal, typhoid is still a major problem. In 1985 there was an estimated global incidence of typhoid of 12.5 million cases each year resulting in over 300000 deaths [3]. The importance of good sanitation and hygiene is well illustrated by experience in Singapore where there has been a steady decline in typhoid from an incidence of 10 per 100 000 population in the 1950s to 1 per 100 000 in the 1980s [4] . Because of the difficulties in preventing typhoid by public health measures or immunisation, in developing countries great reliance is placed on antimicrobial chemotherapy, The mortality of untreated typhoid can be as high as 30%, whereas with appropriate antimicrobial chemotherapy it is < 1 %. In developing countries the antimicrobial agents most readily available for therapy are ampicillin, chloramphenicol and co-trimoxazole. Typhi. A 3-day regimen of oral ofloxacin was safe and highly effective in treating uncomplicated multi-drug resistant typhoid [25], but the effect of such short courses on carriage of S. Typhi needs further exploration. In children, the risks of mortality and morbidity from infection with multiresistant strains greatly outweigh the risk of potential side-effects of fluoroquinolone therapy [37] . For now, empirical therapy of suspected typhoid should be a fluoroquinolone or expanded-spectrum cephalosporin. Unfortunately, ciprofloxacin-resistant strains have already begun to emerge [38,39], and this will further limit the therapeutic options. 
